Amatuximab (MORAb-009) is a monoclonal antibody that binds mesothelin, a cell surface protein on pancreatic, mesothelioma and a subset of other types of tumor cells.
Morphotek said that funding from this grant will support a pre-clinical study to evaluate the potential of Amatuximab alone and in combination with gemcitabine in an adjuvant setting.
Morphotek president and CEO Nicholas Nicolaides said that they were hopeful that the data may bring them one step closer to providing hope for these patients.